Alexander Davis's Avatar

Alexander Davis

@alexanderdavis.bsky.social

Medical Oncologist PhD candidate - all things KRAS and lung cancer

98 Followers  |  202 Following  |  1 Posts  |  Joined: 12.11.2024  |  1.4039

Latest posts by alexanderdavis.bsky.social on Bluesky

Preview
Journal accepts bogus paper requesting removal from mailing list Australian computer scientist Dr Peter Vamplew submitted emphatically titled paper to ‘predatory’ journal and ‘nearly fell off chair’ when it was accepted

www.theguardian.com/australia-ne...
This is great

26.03.2025 07:57 — 👍 2    🔁 0    💬 0    📌 0
Preview
Adjuvant Immunotherapy Should Not be Used in Patients With a Pathologic Complete Response to Neoadjuvant Chemoimmunotherapy

A story of controversy: During my time as Reviews Editor at the Journal of Thoracic Oncology, Alex Adjei, the editor -in-chief accepted my pitch to have these pro/cons. Inspired by some of the sport seen in fun conference debates. www.sciencedirect.com/science/arti...

09.01.2025 19:36 — 👍 12    🔁 3    💬 1    📌 0
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) shows statistically significant and clinically meaningful improvement in overall survival versus osimertinib Median overall survival improvement expected to exceed one year First and only regimen with a survival benefit over current standard of care in first-line treatment of EGFR-mutated lung cancer

Press release: MARIPOSA regimen of first-line amivantamab plus lazertinib shows a significant improvement in overall survival over osimertinib alone in #EGFR NSCLC. Full data to be presented but improvement in median OS expected to be over 12 months.

www.jnj.com/media-center...

07.01.2025 13:34 — 👍 23    🔁 5    💬 0    📌 2

@alexanderdavis is following 20 prominent accounts